This bill makes it easier for drug companies to develop new cancer treatments for children by changing how the FDA reviews these medications. Specifically, it focuses on drugs that target the molecular causes of pediatric cancers—meaning drugs designed to attack specific genetic or cellular features of childhood cancers rather than using a one-size-fits-all approach.

The main change allows companies to test new cancer drugs in combination with existing cancer treatments that are already standard care for kids. Previously, companies had to test new drugs mostly on their own. Now, if a company is developing a new drug that works alongside an established treatment that doctors already use for childhood cancer, they can study them together. This makes sense because kids are often treated with multiple drugs at once, so testing them in realistic combinations could lead to better treatments faster.

The bill also extends a program that gives companies special priority when the FDA reviews new drugs for rare childhood diseases. This "priority voucher" program gets extended through 2030, meaning companies that develop treatments for uncommon pediatric diseases get faster FDA review—a valuable incentive that can speed up how quickly new medicines reach sick children. The bill requires the government to study whether these changes actually work, checking back in 5 to 10 years to see if more childhood cancer drugs are being developed and if kids are getting access to better treatments sooner.